OliX PharmaceuticalsInc (226950) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.081x

Based on the latest financial reports, OliX PharmaceuticalsInc (226950) has a cash flow conversion efficiency ratio of -0.081x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-12.16 Billion ≈ $-8.24 Million USD) by net assets (₩150.08 Billion ≈ $101.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 226950 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

OliX PharmaceuticalsInc - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how OliX PharmaceuticalsInc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

OliX PharmaceuticalsInc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of OliX PharmaceuticalsInc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Anhui Kouzi Distillery Co Ltd SHG:603589	-0.001x
Nexa Resources SA NYSE:NEXA	0.238x
Zhewen Interactive Group Co Ltd SHG:600986	0.038x
Hunan Nanling Industrial Explosive Materials Co Ltd SHE:002096	0.041x
Voyager Technologies, Inc. NYSE:VOYG	-0.098x
Triputra Agro Persada Tbk PT JK:TAPG	0.053x
Topscore Fashion SHG:603608	0.016x
Dynavax Technologies Corporation NASDAQ:DVAX	0.063x

Annual Cash Flow Conversion Efficiency for OliX PharmaceuticalsInc (2016–2025)

The table below shows the annual cash flow conversion efficiency of OliX PharmaceuticalsInc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of OliX PharmaceuticalsInc.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩150.08 Billion ≈ $101.71 Million	₩-15.90 Billion ≈ $-10.78 Million	-0.106x	+93.26%
2024-12-31	₩17.85 Billion ≈ $12.10 Million	₩-28.04 Billion ≈ $-19.01 Million	-1.571x	-273.62%
2023-12-31	₩50.34 Billion ≈ $34.11 Million	₩-21.17 Billion ≈ $-14.35 Million	-0.421x	+9.67%
2022-12-31	₩65.91 Billion ≈ $44.66 Million	₩-30.68 Billion ≈ $-20.79 Million	-0.466x	+54.75%
2021-12-31	₩18.52 Billion ≈ $12.55 Million	₩-19.05 Billion ≈ $-12.91 Million	-1.029x	-1139.29%
2020-12-31	₩45.29 Billion ≈ $30.69 Million	₩-3.76 Billion ≈ $-2.55 Million	-0.083x	+67.67%
2019-12-31	₩41.80 Billion ≈ $28.33 Million	₩-10.73 Billion ≈ $-7.27 Million	-0.257x	-68.76%
2018-12-31	₩54.94 Billion ≈ $37.23 Million	₩-8.36 Billion ≈ $-5.67 Million	-0.152x	+40.64%
2017-12-31	₩18.68 Billion ≈ $12.66 Million	₩-4.79 Billion ≈ $-3.24 Million	-0.256x	+6.67%
2016-12-31	₩12.56 Billion ≈ $8.51 Million	₩-3.45 Billion ≈ $-2.34 Million	-0.275x	--

About OliX PharmaceuticalsInc

KQ:226950 Korea Biotechnology

Market Cap

$1.76 Billion

₩2.60 Trillion KRW

Market Cap Rank

#6741 Global

#177 in Korea

Share Price

₩129300.00

Change (1 day)

+7.04%

52-Week Range

₩34800.00 - ₩207000.00

All Time High

₩207000.00